Secondary antibody deficiency

Expert Review of Clinical Immunology

Volumn 10, Issue 5, 2014, Pages 583-591

  Duraisingham, Sai S ^a   Buckland, Matthew S ^a   Grigoriadou, Sofia ^a   Longhurst, Hilary J ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

antibody; deficiency; hypogammaglobulinemia; immunodeficiency; immunosuppression; infection; rituximab; secondary

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTICONVULSIVE AGENT; AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GOLD; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; PENICILLAMINE; PHENYTOIN; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; VALPROIC ACID; VINCRISTINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY RESPONSE; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BURN; CHRONIC LYMPHATIC LEUKEMIA; CORTICOSTEROID THERAPY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INJURY; LYMPHOMA; MULTIPLE SCLEROSIS; NEPHROTIC SYNDROME; ORGAN TRANSPLANTATION; PATIENT MONITORING; PROTEIN LOSING GASTROENTEROPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY ANTIBODY DEFICIENCY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VACCINATION; CHEMICALLY INDUCED; HEMATOLOGIC NEOPLASMS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PASSIVE IMMUNIZATION; PROCEDURES;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOSUPPRESSIVE AGENTS; INFECTION;

EID: 84898895078     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.902314     Document Type: Review

References (100)

1. Herriot R, Sewell WA. Antibody deficiency. J Clin Pathol 2008;61(9):994-1000
2. Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med 2006;73(2):133-7.140, 143-134
3. Driessen GJ, Dalm VA, van Hagen PM, et al. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica 2013;98(10): 1617-23
4. Ameratunga R, Woon ST, Gillis D, et al. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 2013; 174(2):203-11
5. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008;112(2):277-86
6. Healy MJ. Hypogammaglobulinaemia in the United Kingdom XII. Statistical analyses: prevalence, mortality and effects of treatment. Spec Rep Ser Med Res Counc (GB) 1971;310:115-26
7. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119(7):1650-7
8. Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004;40(2):113-18
9. Baris S, Ercan H, Cagan HH, et al. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J Investig Allergol Clin Immunol 2011;21(7):514-21
10. Blore J, Haeney MR. Primary antibody deficiency and diagnostic delay. BMJ 1989; 298(6672):516-17
11. Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005;58(5):546-7
12. Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency (CVID). J Allergy Clin Immunol 2014. [Epub ahead of print]
13. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 2000;75(10):1039-54
14. Paglieroni T, Caggiano V, MacKenzie MR. Association of bone marrow growth pattern, coexpression of CD14, and B-cell CD5 antigen density in 45 B-chronic lymphocytic leukemia (B-CLL) patients. Ann N Y Acad Sci 1992;651:484-5
15. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992;89(3):374-7
16. Karlsson J, Andreasson B, Kondori N, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 2011;18(6):969-77
17. Murphy K, Travers P, Walport M, Janeway C. Janeway's Immunobiology. Edition 7. Garland Science, New York, US; 2008
18. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(1):99-104
19. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol 2010;159(3):344-50
20. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006;17(9): 1424-7
21. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
22. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13(2):106-11
23. Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013; 15(Suppl 1):S3
24. De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 2012;51(5):833-40
25. Nishio M, Endo T, Fujimoto K, et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 2009;82(2):143-7
26. Boumans MJ, Thurlings RM, Gerlag DM, et al. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthritis Rheum 2011;63(11):3187-94
27. Corsiero E, Bombardieri M, Manzo A, et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012;145(1-2):62-7
28. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008;67(3):402-8
29. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56(3):772-8
30. Walsh CA, Fearon U, FitzGerald O, et al. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 2008;26(4):656-8
31. Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007;46(1):29-36
32. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11(4):R131
33. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009;11(4): R123
34. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25): 2572-81
35. Castro AP, Redmershi MG, Pastorino AC, et al. Secondary hypogammaglobilinemia after use of carbamazepine: case report and review. Rev Hosp Clin Fac Med Sao Paulo 2001;56(6):189-92
36. Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;38(6):433-6
37. Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010;91(3):501-8
38. Nishio M, Fujimoto K, Yamamoto S, et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 2007;137(4):349-54
39. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012;66(12): 1177-81
40. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine (Baltimore) 2003;82(5):299-308
41. Alarcon GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45(2):191-202
42. Edwards CJ, Lian TY, Badsha H, et al. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003;12(9): 672-6
43. Barber C, Gold WL, Fortin PR. Infections in the lupus patient: perspectives on prevention. Curr Opin Rheumatol 2011; 23(4):358-65
44. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999;92(1): 34-48
45. Fernandez-Castro M, Mellor-Pita S, Citores MJ, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum 2007;36(4):238-45
46. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54(2):628-34
47. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59(8):1074-81
48. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007;46(7): 1157-60
49. Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011;13(4):R112
50. Becerra E, Cambridge G, de la Torre I, Leandro MJ. Long-term safety of rituximab in patients with rheumatoid arthritis. Int J Clin Rheumatol 2012;7(4):383-90
51. Venhoff N, Effelsberg NM, Salzer U, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 2012;7(5):e37626
52. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62(9):2625-32
53. Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 2013;13(10): 2601-10
54. Yip NH, Lederer DJ, Kawut SM, et al. Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med 2006;173(8):917-21
55. Bousfiha AA, Jeddane L, Ailal F, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 2013;33(6):1078-87
56. Yomota M, Amano I, Horita N, et al. Serum immunoglobulin G is a marker for the risk of opportunistic infection in steroid-dependent severe asthmatic patients. Intern Med 2012;51(19):2715-19
57. Kawano T, Matsuse H, Obase Y, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol 2002;128(3):240-3
58. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11(6):954-63
59. Pereira LF, Sanchez JF. Reversible panhypogammaglobulinemia associated with phenytoin treatment. Scand J Infect Dis 2002;34(10):785-7
60. Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clin Exp Immunol 1975;20(2):273-85
61. Ranua J, Luoma K, Auvinen A, et al. Serum IgA, IgG, and IgM concentrations in patients with epilepsy and matched controls: a cohort-based cross-sectional study. Epilepsy Behav 2005;6(2):191-5
62. Spickett GP, Gompels MM, Saunders PW. Hypogammaglobulinaemia with absent B lymphocytes and agranulocytosis after carbamazepine treatment. J Neurol Neurosurg Psychiatry 1996;60(4):459
63. Go T. Carbamazepine-induced IgG1 and IgG2 deficiency associated with B cell maturation defect. Seizure 2004;13(3): 187-90
64. Ozaras N, Goksugur N, Eroglu S, et al. Carbamazepine-induced hypogammaglobulinemia. Seizure 2012; 21(3):229-31
65. Aucouturier P, Couderc LJ, Gouet D, et al. Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome. Clin Exp Immunol 1986;63(1): 234-40
66. Crum-Cianflone NF, Collins G, Defang G, et al. Immunoglobulin G subclass levels and antibody responses to the 2009 influenza A (H1N1) monovalent vaccine among human immunodeficiency virus (HIV)-infected and HIV-uninfected adults. Clin Exp Immunol 2012;168(1):135-41
67. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989;3(1):37-9
68. de Moraes-Pinto MI, Farhat CK, Hanson LA, et al. IgA deficiency associated with human immunodeficiency virus infection. Rev Inst Med Trop Sao Paulo 1993;35(2):209-10
69. Olopoenia L, Young M, White D, et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 1997;89(8):543-7
70. Junker AK, Ochs HD, Clark EA, et al. Transient immune deficiency in patients with acute Epstein-Barr virus infection. Clin Immunol Immunopathol 1986;40(3): 436-46
71. South MA, Montgomery JR, Rawls WE. Immune deficiency in congenital rubella and other viral infections. Birth Defects Orig Artic Ser 1975;11(1):234-8
72. Palacin PS, Castilla Y, Garzon P, et al. Congenital rubella syndrome, hyper-IgM syndrome and autoimmunity in an 18-year-old girl. J Paediatr Child Health 2007;43(10):716-18
73. Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010;236:176-89
74. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002;109(6): 1001-4
75. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6): 1354-60.e1354
76. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010;137(1): 21-30
77. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011;31(3): 315-22
78. Co-operative group for the study of immunoglobulins in CLL. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319(14):902-7
79. Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009;39(1):18-29
80. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996;81(2): 121-6
81. Gunther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol 2013;57(7):527-35
82. Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343(8905):1059-63
83. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21(18):3431-9
84. Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009;115(8):1680-91
85. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002- Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23(36): 9219-26
86. Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem 2013;50(Pt 6):517-19
87. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2012;130(3 Suppl):S1-24
88. Turvey SE, Bonilla FA, Junker AK. Primary immunodeficiency diseases: a practical guide for clinicians. Postgrad Med J 2009; 85(1010):660-6
89. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007;149(3):410-23
90. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. (CDC). General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(2): 1-64
91. Public Health England DoH. Immunisation against infectious disease. In: Salisbury D, Ramsay M, editors. The 'Green' Book. The Stationery Office, London, UK; 2013
92. Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009;155(2): 147-55
93. Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol 2014. [Epub ahead of print]
94. Hjalmarson O, Hanson LA, Nilsson LA. IgA deficiency during D-penicillamine treatment. BMJ 1997;1(6060):549
95. Leickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. J Pediatr 1986;108(3): 481-2
96. So AK, Peskett SA, Webster AD. Hypogammaglobulinaemia associated with gold therapy. Ann Rheum Dis 1984;43(4): 581-2
97. Eom TH, Lee HS, Jang PS, Kim YH. Valproate-induced panhypogammaglobulinemia. Neurol Sci 2013;34(6):1003-4
98. Peterson PA, Berggard I. Urinary immunoglobulin components in normal, tubular, and glomerular proteinuria: quantities and characteristics of free light chains, IgG, igA, and Fc-gamma fragment. Eur J Clin Invest 1971;1(4):255-64
99. Strober W, Wochner RD, Carbone PP, Waldmann TA. Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest 1967;46(10):1643-56
100. Ameratunga R, Casey P, Parry S, Kenedi C. Hypogammaglobulinemia factitia-Munchausen syndrome masquerading as common variable immune deficiency. Allergy Asthma Clin Immunol 2013;9(1):36